CTOs on the Move

QRS Diagnostic

www.qrsdiagnostic.com

 
"Founded in 1995 and headquartered in Plymouth, Minnesota, QRS Diagnostic designs and develops software-based medical devices, built into computer cards and USB modules, which cost 25 percent to 50 percent less than traditional device products. ""QRS is"
  • Number of Employees: 25-100
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details

Similar Companies

ONRAD

ONRAD is a full service physician-owned radiology provider offering customized radiology services including teleradiology solutions, on-site radiology coverage, subspecialty teleradiology interpretations, and quality assurance programs.

Central Blood Bank

Central Blood Bank is a Pittsburgh, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Cardiac Concepts

Cardiac Concepts is a Hopkins, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Imaging Healthcare Specialists

Imaging Healthcare Specialists is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Natera

Natera Inc. is a genetic testing company that specializes in analyzing tiny quantities of DNA for reproductive health. Natera operates a CLIA-certified laboratory in San Carlos, Calif., providing a host of preconception and prenatal genetic testing services. Test offerings include pre-implantation genetic diagnosis to identify chromosomal anomalies or inherited genetic conditions in embryos generated during an IVF cycle; products-of-conception testing following miscarriage to analyze fetal chromosomes and understand the cause of the pregnancy loss; non-invasive prenatal testing to determine paternity; carrier screening to detect whether parents carry genetic variations that may result in disease in the child; and Panorama, a safe, simple test for pregnant women that identifies the most common chromosomal anomalies in a fetus as early as nine weeks of gestation. Natera's PreNATUS clinical trial for non-invasive screening of fetal chromosomal anomalies is funded by the NIH and is being conducted by the leaders in maternal-fetal medicine in the United States. These tests were developed by Natera, a laboratory certified under the Clinical Laboratory Improvement Amendments (CLIA). They have not been cleared or approved by the U.S. Food and Drug Administration (FDA). In August, Natera was selected by the World Economic Forum as a Technology Pioneer for innovations in prenatal care. For more information, visit www.natera.com.